+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Heart Failure - Pipeline Insight, 2021

  • ID: 5240440
  • Clinical Trials
  • July 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • Acceleron Pharma Inc.
  • AstraZeneca
  • Cardiora
  • Innolife Co., Ltd.
  • Merck Sharp & Dohme Corp.
  • Novo Nordisk A/S
This Heart failure - Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Heart failure Understanding


Heart failure: Overview


Heart Failure, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are disrupted. Certain conditions, such as narrowed arteries in the heart (coronary artery disease) or high blood pressure, gradually leave the heart too weak or stiff to fill and pump efficiently. Heart failure can be diagnosed based on the medical and family history, a physical exam, and test results. Treating heart failure depends on the severity of the condition. Diagnostic tests include: electrocardiogram, chest X-Ray, echocardiography etc. Treatments usually include heart-healthy lifestyle changes, medicines, and ongoing care.

Heart failure - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart failure pipeline landscape is provided which includes the disease overview and Heart failure treatment guidelines. The assessment part of the report embraces, in depth Heart failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Heart failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart failure.

Heart failure Emerging Drugs Chapters


This segment of the Heart failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart failure Emerging Drugs


Finerenone: Bayer HealthCare Pharmaceuticals

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block many of the harmful effects of mineralocorticoid receptor (MR) overactivation. MR overactivation is a major driver of kidney and cardiovascular damage through inflammatory and fibrotic processes. It is in phase III stage of development to treat heart failure.

IONIS-AGT-LRx: Ionis Pharmaceuticals

IONIS-AGT-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of angiotensinogen to decrease blood pressure in patients with treatment resistant hypertension (TRH). Despite availability of generic antihypertensive agents, TRH is a major contributor to cardiovascular and renal disease. It is in phase II stage of development to treat chronic heart failure.

Heart failure: Therapeutic Assessment


This segment of the report provides insights about the different Heart failure drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Heart failure


There are approx. 100+ key companies which are developing the therapies for Heart failure. The companies which have their Heart failure drug candidates in the most advanced stage, i.e. phase III include, Bayer HealthCare Pharmaceuticals.

Phases


This report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Heart failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart failure: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure drugs.

Heart failure Report Insights

  • Heart failure Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Heart failure Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Heart failure drugs?
  • How many Heart failure drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Heart failure therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Heart failure and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Bayer HealthCare Pharmaceuticals
  • Ionis Pharmaceuticals
  • Heartseed Inc.
  • AstraZeneca
  • Amgen
  • Sardocor Corp.
  • Intra-Cellular Therapies
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Palatin Technologies
  • Cardiora
  • Zensun Sci. & Tech. Co., Ltd.
  • Biopeutics Co., Ltd
  • Innolife Co., Ltd.
  • SQ Innovation
  • scPharmaceuticals
  • Mesoblast, Inc
  • PhaseBio Pharmaceuticals
  • Salubris Biotherapeutics Inc
  • Actelion Pharmaceuticals
  • Torrent Pharmaceuticals Limited
  • Novo Nordisk A/S
  • Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.
  • Merck Sharp & Dohme Corp.
  • Cardior Pharmaceuticals GmbH
  • Pfizer
  • MyoKardia, Inc.
  • TransThera Biosciences Co., Ltd
  • Acceleron Pharma Inc.
  • Asklepios Biopharmaceutical, Inc.
  • Bial

Key Products

  • Finerenone
  • IONIS-AGT-LRx
  • HS 001
  • AZD 4831
  • Omecamtiv Mecarbil
  • SRD-001
  • ITI-214
  • BMS-986259
  • LY3461767
  • PL-3994
  • CRD-102
  • rhNRG-1
  • INL1
  • SQIN-01
  • Furoscix Infusor
  • Allogeneic Mesenchymal Precursor Cells (MPC)
  • PB1046
  • JK07
  • Macitentan
  • TRC041266
  • Semaglutide
  • TSG-01
  • Ertugliflozin
  • CDR132L
  • Sildenafil Citrate
  • Mavacamten
  • TT-00920
  • Sotatercept
  • NAN-101
  • BIA 5-1058
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acceleron Pharma Inc.
  • AstraZeneca
  • Cardiora
  • Innolife Co., Ltd.
  • Merck Sharp & Dohme Corp.
  • Novo Nordisk A/S

IntroductionExecutive Summary
Heart failure: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Heart failure - Analytical Perspective
In-depth Commercial Assessment
  • Heart failure companies' collaborations, Licensing, Acquisition -Deal Value Trends

Heart failure Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

Finerenone: Bayer HealthCare Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

IONIS-AGT-LRx: Ionis Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

NAN-101: Asklepios BioPharmaceutical
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical and Discovery Stage Products
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Heart failure Key CompaniesHeart failure Key ProductsHeart failure- Unmet NeedsHeart failure- Market Drivers and BarriersHeart failure- Future Perspectives and ConclusionHeart failure Analyst ViewsHeart failure Key CompaniesAppendix
List of Tables
Table 1 Total Products for Heart failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Heart failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Acceleron Pharma Inc.
  • Actelion Pharmaceuticals
  • Amgen
  • Asklepios Biopharmaceutical, Inc.
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals
  • Biopeutics Co., Ltd
  • Bristol Myers Squibb
  • Cardior Pharmaceuticals GmbH
  • Cardiora
  • Eli Lilly and Company
  • Heartseed Inc.
  • Innolife Co., Ltd.
  • Intra-Cellular Therapies
  • Ionis Pharmaceuticals
  • Merck Sharp & Dohme Corp.
  • Mesoblast, Inc
  • MyoKardia, Inc.
  • Novo Nordisk A/S
  • Palatin Technologies
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Salubris Biotherapeutics Inc
  • Sardocor Corp.
  • scPharmaceuticals
  • Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.
  • SQ Innovation
  • Torrent Pharmaceuticals Limited
  • TransThera Biosciences Co., Ltd
  • Zensun Sci. & Tech. Co., Ltd.
Note: Product cover images may vary from those shown